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1. The upper part shows the results of the SHARP-trial, the lower part
s the results of the APT. The bars are showing the median time from study
y to symptomatic progression (light blue) and, further on, to median overall
ival (dark blue).To the Editor:
A recent review published in the Journal of Hepatology discusses
the opportunities for chemotherapy in hepatocellular carcinoma
(HCC) [1]. In this review, the authors conclude that ‘‘Sorafenib is
currently regarded as the standard of care in selected patients with
advanced HCC based on two large randomised placebo controlled
trials’’ [2,3]. Furthermore, the introduction suggests its use as a
palliative therapeutic. But what actually deﬁnes a palliative treat-
ment? A decent deﬁnition of palliative chemotherapy is given by
V.R. Archer in 1999: ‘‘Palliative chemotherapy is deﬁned as treat-
ment in circumstances where the impact of intervention is insufﬁ-
cient to result in major survival advantage, but does affect
improvement in terms of tumor-related symptoms, and where the
palliation/toxicity trade-off from treatment clearly favors symptom
relief’’ [4].
Assuming sorafenib to be a palliative treatment, the data of
the SHARP [2] and the Asian Paciﬁc Trial (APT) [3] can be used
to extrapolate the medians of asymptomatic and symptomatic
time of survival. In both studies, the eligibility criteria included
an Eastern Cooperative Oncology Group (ECOG) performance
status score of 2 or less (i.e. ranging from full active: 0, to
capable of self-care but unable to work: 2) [5]. It thus seems
ﬁne to assume that the patients entered the study with a pre-
served quality of life. Furthermore, both studies give data for
the cut-off, where an asymptomatic patient changes to a symp-
tomatic one: the time to symptomatic progression (TTSP). Both
studies deﬁned symptomatic progression (SP) as death, a
decline to an ECOG performance status score of 4 (i.e. com-
pletely disabled, conﬁned to bed, and chair) [5] or an increase
of 4 points in the Hepatobiliary Symptom Index (FISH-8) ques-
tionnaire [6]. Last but not least, both studies also report overall
survival.
The SHARP trial reported a median overall survival (OS) of
10.9 months vs. 7.9 months for sorafenib vs. placebo respectively
(p <0.001), and a median time to symptomatic progression of
4.1 months vs. 4.9 months (p = 0.77) [2]. The APT reported a med-
ian OS of 6.5 months vs. 4.2 months for sorafenib vs. placebo
(p = 0.14), and a median TTSP of 3.5 months vs. 3.4 (p = 0.50)
[3]. Assuming that patients were asymptomatic at the beginning
of the study, the majority of patients remained asymptomatic
until the median of TTSP was reached. Beyond this, the majority
of patients was symptomatic and stayed so until the median of
overall survival was reached (Fig. 1).While sorafenib deﬁnitely marks a milestone in the treatment
of non-resectable HCC, both trials only show a prolongation of
survival with minimal to no impact on the time to symptomatic
progression (in both trials, this outcome was non-signiﬁcant).
Even thought sorafenib may not reﬂect the characteristics of an
ideal ‘‘palliative drug’’, a patient’s wish for treatment in the set-
ting of non-curable disease should never be underestimated.
For example, in 104 women with breast cancer who already
had three cycles of cyclophosphamide, methotrexate, and 5-ﬂuo-
rouracil (CMF) as adjuvant treatment, the patients were asked to
rate the survival beneﬁt that would justify 6 months of such a
treatment. Surprisingly, 50% of all patients would participate in
another 6 months of treatment for a small 1% gain in 5 year-sur-
vival [7].
Thus, the prescribing doctor and his or her patients should
be aware that while sorafenib may prolong the median survival
of 2–3 months [2,3], the symptoms associated with the disease
or its treatment remain untouched. For patients in whom the
main desire is for a treatment ‘‘to buy them some time’’, sorafe-
nib remains a good option. However, the patient must then be
aware of all the possible adverse events, the possible longer
symptomatic course, and the substantial costs of the treatment
involved (about 2400 EUR per month). In the end, treatment
deferral also remains a valid choice and accepting the natural
course of a disease may indeed be the best option for someol. 57 j 221–232
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patients. This memorandum wants to point out the missing dif-
ference in TTSP and encourage clinicians to discuss both courses
with their patients.
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To the Editor:
The main focus of our paper concerns the potential role of cyto-
toxic chemotherapy, which needs to be considered in the context
of other standards of care [1]. As stated, the current standard of
care for advanced HCC is sorafenib. An exhaustive review of the
SHARP [2] and AP [3] trial data was not within the scope of our
review since these have been covered extensively in previous
publications. We do, however, highlight both the survival beneﬁt
and the toxicity associated with sorafenib. Survival remains the
primary end point for most phase III trials and is both robust
and, as Dr. Strebel points out, relevant to patients. Similarly, the
assessment of toxicity using National Cancer Institute’s Common
Terminology Criteria is well validated. However, the assessment
of time to symptomatic progression (TTSP) was done using
change in performance status and the Functional Assessment of
Cancer Therapy (FACT) Hepatobiliary Symptom Index 8 (FHSI-
8). The FHSI-8 is a tool developed to assess symptoms in hepatob-
iliary cancer patients in general and is not speciﬁc for HCC
patients. It has been validated in only one small study of 51
patients of which only 10 had HCC [4]. Furthermore, the ability
of the tool to detect clinically meaningful changes over time
has not been determined. Although TTSP was a primary end
point, the trial was not speciﬁcally powered to detect a difference
in TTSP. Hence, the lack of difference between the control and
treatment group may be due to the use of an insensitive tool, lack
of statistical power or real.
In discussing the option of sorafenib with patients, it is clearly
important to fully inform them of the known beneﬁts and the
main toxicities. However, unless the patient has to pay person-
ally, we do not agree that patients with advanced cancer should
be advised of the cost of the treatment. Such information implies
that the patient must judge whether their life is worth the cost.
We believe the question of cost-effectiveness is one for the
healthcare providers.Conﬂict of interest
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